New treatment for advanced ovarian cancer using a small molecule inhibitor
Official title: Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
Funded at Up Therapeutics, INC. · NIH-10916490 · Data updated 2026-11-12
This study is testing a new drug designed to help treat advanced ovarian cancer by targeting a specific part of cancer cells, and it’s for patients looking for better options since current treatments can have tough side effects.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Up Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Frederick, UNITED STATES) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,178,998 |
| NIH project number | 5R44CA278176-02 |
| Project ID | NIH-10916490 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced epithelial ovarian cancer who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage ovarian cancer or those who have not been diagnosed with ovarian cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel small molecule inhibitor targeting RPN13 to treat advanced ovarian cancer, a condition that currently has limited effective therapies. The approach involves creating a drug that can effectively penetrate solid tumors and overcome the limitations of existing proteasome inhibitors, which often cause severe side effects. By targeting the proteasome's function in cancer cells, the treatment aims to reduce the accumulation of harmful proteins that contribute to cancer progression. Patients may have the opportunity to participate in trials assessing the safety and efficacy of this new treatment.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment option for patients with advanced ovarian cancer.
How similar studies have gone: While proteasome inhibitors have shown success in treating liquid tumors, this approach is novel for solid tumors like ovarian cancer and has not been extensively tested.
Where this research is happening
-
Up Therapeutics, INC.
Frederick, United States Active
Researchers
- Principal investigator: Anchoori, Ravi Kumar — Up Therapeutics, INC.
- Study coordinator: Anchoori, Ravi Kumar
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.